Kezar Life Sciences, Inc. Cashflow Statement

Ask AI

Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated Statements of Cash Flows

In millions of USD, except per-share amounts

	FY2025 12 months to Dec 31, 2025	FY2024 12 months to Dec 31, 2024	FY2023 12 months to Dec 31, 2023	FY2022 12 months to Dec 31, 2022	FY2021 12 months to Dec 31, 2021
Cash flows from operating activities:
Net loss
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization
Stock-based compensation
Amortization of premiums and discounts on marketable securities
Amortization of debt discount and issuance costs and other non-cash interest
Loss on debt extinguishment
Impairment loss of property and equipment
Impairment loss of right-of-use asset
Reclassification of currency translation loss
Loss on disposal of property and equipment
Changes in operating assets and liabilities
Prepaid expenses and other current assets
Other assets
Accounts payable and accrued liabilities
Operating lease liabilities and other liabilities
Operating lease asset and liabilities

Net cash used in operating activities
Cash flows from investing activities:
Purchases of property and equipment
Purchases of marketable securities
Maturities of marketable securities
Proceeds from sale of equipment
Net cash provided by investing activities
Cash flows from financing activities:
Proceeds from issuance of common stock under at-the-market offerings and warrants, net of issuance costs
Proceeds from long-term debt, net of debt discount and issuance costs of $469
Proceeds from sale of common stock and pre-funded warrants in public offerings, net of offering costs
Repayment of loan principal and final fee
Proceeds from issuance of common stock under employee stock incentive plans
Net cash (used in) provided by financing activities

Effect of exchange rate changes on cash and cash equivalents
Net increase (decrease) in cash and cash equivalents
Cash and cash equivalents at the beginning of period
Cash and cash equivalents at the end of period
Supplemental disclosures of noncash investing and financing information:
Reclassification of employee stock liability to equity upon vesting
Purchase of property and equipment in accounts payable
Par value of common stock upon cashless exercise of prefunded warrants
Unpaid offering costs in accrued liabilities

Supplemental disclosures
Cash paid for interest

Comments